JPMorgan raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $25 from $20 and keeps a Neutral rating on the shares. The firm updated the company’s model post the approval of Aqvesme.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AGIO:
- Agios Pharma: Broad Aqvesme Label, Premium Pricing, and Manageable Safety Profile Support Buy Rating and 54.5% Upside Potential
- Agios Pharmaceuticals: Thalassemia Approval, Premium Pricing, and Manageable REMS Drive Higher Target and Undervalued Buy Thesis
- Agios: FDA Approval of Aqvesme in Thalassemia Unlocks Transformational Market Opportunity, Supporting Buy Rating and Higher Target
- Agios Pharmaceuticals price target raised to $62 from $48 at H.C. Wainwright
- Agios Pharmaceuticals price target raised to $38 from $32 at Truist